| Literature DB >> 35174856 |
Pete Heinzelman1, Jonathan C Greenhalgh1,2, Philip A Romero1,2.
Abstract
Understanding how severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) interacts with different mammalian angiotensin-converting enzyme II (ACE2) cell entry receptors elucidates determinants of virus transmission and facilitates development of vaccines for humans and animals. Yeast display-based directed evolution identified conserved ACE2 mutations that increase spike binding across multiple species. Gln42Leu increased ACE2-spike binding for human and four of four other mammalian ACE2s; Leu79Ile had an effect for human and three of three mammalian ACE2s. These residues are highly represented, 83% for Gln42 and 56% for Leu79, among mammalian ACE2s. The above findings can be important in protecting humans and animals from existing and future SARS-CoV-2 variants.Entities:
Keywords: SARS-CoV-2; angiotensin-converting enzyme II; directed evolution; vaccine; yeast surface display
Mesh:
Substances:
Year: 2022 PMID: 35174856 PMCID: PMC9005050 DOI: 10.1093/protein/gzab035
Source DB: PubMed Journal: Protein Eng Des Sel ISSN: 1741-0126 Impact factor: 1.650